Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRB-001 Vaccination in Parkinson's Disease Patients Previously Treated With aSyn Immunotherapy
NCT07777484Phase 1Recruiting
- Sponsor
- Tridem Bioscience
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TRB-001 in Parkinson's disease (PD), sponsored by Tridem Bioscience. Primary endpoint: Incidence of local and systemic treatment-emergent adverse events at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
TRB-001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07777484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07777484.